In 70 Cuban patients with high-grade glioma, adding the anti-EGFR antibody nimotuzumab to radiotherapy gave a median survival of 17.8 months against 12.6 months with placebo. The abstract's background says the antibody does not cause the skin toxicity of other anti-EGFR antibodies; that is not reported as a result of this trial.
A randomised, double-blind, multicentre trial in 41 patients with anaplastic astrocytoma and 29 with glioblastoma, who received radiotherapy with six weekly doses of 200 mg nimotuzumab or placebo, then maintenance every three weeks for a year. The trial is registered in the Cuban National Register for clinical trials (No. 1745).
A small randomised trial of nimotuzumab with radiotherapy for high-grade glioma. Cuba's regulator CECMED lists adult high-grade glioma with radiotherapy among the indications of CIMAher (nimotuzumab), registered there since 19 February 2002.
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), CIMAB, EGFR.
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), CIMAB.
Shares Nimotuzumab, EGFR.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/